Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?-Reference-Cited by-同舟云学术

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?

Published:2021-03 Issue:10277 Volume:397 Page:879-880
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Robertson John F R,Sewell Herb F,Stewart Marcia

Publisher

Elsevier BV

Subject

General Medicine

Reference9 articles.

1. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence;Chodick;MedRxiv,2021

2. Estimating real-world COVID-19 vaccine effectiveness in Israel;Aran;medRxiv,2021

3. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial;Folegatti;Lancet,2020

4. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination;Widge;N Engl J Med,2021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 22 Vaccine Trial Designs;Principles and Practice of Emergency Research Response;2024

2. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study;The Lancet Public Health;2023-03

3. Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2;PLOS Computational Biology;2022-03-25

4. A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines;AAPS PharmSciTech;2022-03-21

5. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization;BMC Medicine;2022-03-17